Compare Boston Scientific Corporation (BSX) vs e l f Beauty Inc (ELF) Price & Performance

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

ELF Beauty trades at $92.62, down 2.75% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $1.75 surpassing the $0.714 expectation, and revenue growth remains robust at 36% in Q1 2027. Analyst sentiment is mixed with a 46.43% buy rating, while technical indicators show overbought RSI levels but bullish moving averages. Recent news highlights expansion into hair care and a $50 million tariff windfall boosting profitability.

The outlook for ELF is positive due to sustained revenue growth and strategic expansions, but risks include high valuation multiples and reliance on acquisitions for growth. The stock's current price is near the consensus target of $91.14, suggesting limited upside unless earnings continue to exceed expectations. Investors should weigh the strong operational performance against elevated P/E and EV/EBITDA ratios.